Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

R2-CHOP Doesn’t Improve Survival in DLBCL

Publish date:: July 24, 2019

Key clinical point: Adding lenalidomide to R-CHOP did not improve progression-free or overall survival in patients with newly diagnosed ABC-type diffuse large B-cell lymphoma (DLBCL).

Major finding: The median progression-free survival was not reached in either trial arm.

Study details: A randomized, phase 3 trial comparing R-CHOP, with or without lenalidomide, in 570 patients with DLBCL.

Disclosures: The ROBUST study was funded by Celgene. Dr. Vitolo reported consulting and speaker’s bureau fees and research funding from the company.

Citation:

Vitolo U et al. 15-ICML, Abstract 005.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,